AstraZeneca’s deadly deception: Heart drug Brilinta exposed as ineffective, increasing heart attack risks

Millions of vulnerable heart patients have been betrayed by AstraZeneca, a pharmaceutical giant with a disturbing track record of manipulating clinical trial data to push dangerous drugs onto an unsuspecting public. Now, top medical experts are sounding the alarm over Brilinta (ticagrelor), a blood-thinning drug falsely marketed as a lifesaver for acute coronary syndrome. Shockingly, mounting evidence reveals that AstraZeneca misreported safety data, concealing the drug’s alarming inefficacy—and even its potential to increase heart attack risks. This isn’t just corporate negligence; it’s a calculated deception that has put millions of lives at stake while lining the pockets of Big Pharma executives.

Key points:

AstraZeneca’s Brilinta, approved in 2011, was touted as a breakthrough for preventing fatal heart attacks—but experts now say trial data was "seriously misreported."

The BMJ investigation found key trial results were inaccurately reported, with nearly a quarter of critical platelet readings omitted from FDA submissions.

Some patients in trials experienced increased platelet aggregation—the exact opposite of what Brilinta is supposed to prevent—raising fears the drug may worsen clotting risks.

Despite red flags, AstraZeneca continues to defend the drug, while regulators turn a blind eye to the mounting evidence of fraud.

Over 45,000 NHS prescriptions are filled monthly for Brilinta, meaning countless patients are unknowingly taking a drug that may do more harm than good.

Natural alternatives - like nattokinase, hawthorne, pomegranate, and garlic offer better protection.

A history of deception: AstraZeneca’s deadly track record

This isn’t the first time AstraZeneca has been caught manipulating data to push a dangerous drug. The company’s COVID-19 vaccine was linked to deadly blood clots, with government reports confirming 437 cases and 78 deaths in the UK alone. The same story unfolded with their ovarian cancer drug and psyche meds for children. Now, history repeats itself as Brilinta faces similar scrutiny.

Dr. Victor Serebruany, a cardiovascular pharmacology expert at Johns Hopkins University, has warned for over a decade that something was "obviously wrong" with Brilinta’s trial data. "If doctors had known what happened in these trials, they would never have started using ticagrelor," he told The BMJ. Yet, AstraZeneca—backed by complicit regulators—brushed aside concerns, prioritizing profits over patient safety.

The smoking gun: Missing data and manipulated results

The BMJ’s investigation uncovered damning evidence that AstraZeneca’s clinical trials excluded critical platelet readings that would have exposed Brilinta’s flaws. In one trial, over 60 out of 282 machine readings were mysteriously omitted from FDA submissions—readings that showed higher platelet activity, suggesting the drug failed to prevent clotting as promised.

Even more alarming, some patients experienced dramatic increases in platelet aggregation—essentially, their blood thickened dangerously, raising their risk of heart attacks and strokes. Yet, these findings were buried, allowing Brilinta to sail through approval while putting millions at risk.

The FDA and UK’s MHRA have long been accused of rubber-stamping dangerous drugs under pressure from pharmaceutical lobbyists. Brilinta’s approval followed the same playbook: questionable data, ignored warnings, and a rush to market. Now, with lives on the line, regulators remain eerily silent.

Meanwhile, AstraZeneca continues to gaslight the public, insisting, "We are confident in the integrity of the trials." But confidence doesn’t erase the bodies piling up—patients who trusted a system rigged against them.

The alternative: Rejecting Big Pharma’s deadly lies

Natural alternatives, from lifestyle changes to proven therapies like nattokinase (a potent blood-thinning enzyme), offer safer solutions without Big Pharma’s deadly side effects. Nattokinase is a powerful fibrinolytic enzyme derived from fermented soybeans, known for its ability to break down blood clots and improve circulation. Studies suggest it may help regulate blood pressure, reduce arterial stiffness, and support cardiovascular health by mimicking the body’s natural clot-dissolving processes. Unlike synthetic blood thinners, nattokinase works synergistically with the body’s systems, offering a gentler yet effective approach to maintaining optimal blood flow.

In addition to nattokinase, several heart-healthy herbs and natural compounds can further support cardiovascular wellness:

Hawthorne – Rich in antioxidants, it strengthens heart muscle function, improves blood flow, and helps regulate blood pressure.

Pomegranate – Its potent polyphenols enhance nitric oxide production, reducing arterial plaque and improving endothelial health.

Garlic – Contains allicin, which lowers cholesterol, reduces blood pressure, and acts as a natural anticoagulant.

Cayenne pepper - Capsules of cayenne pepper deliver capsaicin, which helps thin the blood, reducing blood pressure.

Turmeric (Curcumin) – Fights inflammation, prevents arterial damage, and supports healthy circulation.

Ginger – Promotes vasodilation, reduces platelet aggregation, and aids in maintaining healthy blood pressure levels.

The Brilinta scandal is just the latest proof that pharmaceutical companies cannot be trusted. Until regulators hold them accountable, patients must arm themselves with the truth—because their lives depend on it.

Check out Heart.News for the latest on cardiovascular health.

Sources include:

Dailymail.co.uk

NaturalNews.com

NaturalNews.com

NaturalNews.com

Heart.news